

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 1, 2026

[survminer](#)

RRID:SCR_021094

Type: Tool

Proper Citation

survminer (RRID:SCR_021094)

Resource Information

URL: <https://rdocumentation.org/packages/survminer/versions/0.4.9>

Proper Citation: survminer (RRID:SCR_021094)

Description: Software R package provides functions for facilitating survival analysis and visualization.

Resource Type: data visualization software, data analysis software, software application, software resource, data processing software

Keywords: survival analysis, survival visualization, R

Availability: Free, Available for download, Freely available

Resource Name: survminer

Resource ID: SCR_021094

License: GPL-2

Record Creation Time: 20220129T080353+0000

Record Last Update: 20260801T042832+0000

Ratings and Alerts

No rating or validation information has been found for survminer.

No alerts have been found for survminer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 92 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. *JGH open : an open access journal of gastroenterology and hepatology*, 10(1), e70331.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. *Molecular cancer therapeutics*, 24(4), 550.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1069.

Egea-Rodriguez S, et al. (2025) RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. *Clinical and translational medicine*, 15(1), e70094.

Wu Z, et al. (2025) A dual-targeting strategy to inhibit colorectal cancer liver metastasis via tumor cell ferroptosis and cancer-associated fibroblast reprogramming. *Bioactive materials*, 52, 73.

Lakbir S, et al. (2025) Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers. *NPJ precision oncology*, 9(1), 140.

Krishnan T, et al. (2025) Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. *Cancer research communications*, 5(1), 66.

Mayer M, et al. (2025) Deciphering the cellular tumor microenvironment landscape in salivary gland carcinomas using multiplexed imaging mass cytometry. *Journal of experimental & clinical cancer research : CR*, 44(1), 288.

Mazambani S, et al. (2025) Targeting the Glucose-Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth. *Cancer research communications*, 5(6), 921.

Scheurlen KM, et al. (2025) Itaconate and obesity-related hormones promote tumor progression - new insights on metabolic dysfunction in early-onset colon cancer. *Frontiers in immunology*, 16, 1572985.

Labaf M, et al. (2025) Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. *Molecular cancer therapeutics*, 24(5), 772.

Embaie BT, et al. (2025) Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State. *Cancer research*, 85(6), 1015.

Chiang AC, et al. (2025) Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents. *JTO clinical and research reports*, 6(9), 100829.

Hu Q, et al. (2025) Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy. *BJC reports*, 3(1), 52.

Mout L, et al. (2025) Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate Cancer. *bioRxiv : the preprint server for biology*.

Young AA, et al. (2025) PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer. *RNA (New York, N.Y.)*, 31(11), 1599.

Jin D, et al. (2025) Unveiling the prognostic and immunological role of IFI44 in glioma. *Annals of medicine*, 57(1), 2593209.

Honor?? N, et al. (2025) Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(22), 4790.

Xia J, et al. (2025) BDNF is a prognostic biomarker involved in the immune infiltration of lung adenocarcinoma and associated with programmed cell death. *Oncology letters*, 29(4), 191.